fbpx Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science.

Cue Health Receives FDA Approval for COVID-19 Test, Larry Smarr Retires, Quidel Receives BARDA Funding for Point-of-Care Diagnostic Assay

  • 2020-06-11T19:00:00.000+0000
  • California
  • Author: Lauren Panetta

6/12/20 – Gilead

Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe

6/12/20 – Cue Health

Cue Health Receives FDA Emergency Use Authorization for Its Rapid, Portable, Molecular Point-of-Care COVID-19 Test

6/11/20 – Quidel

Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19

6/11/20 – Confirm BioSciences

COVID-19 Antibody Test Offered by Confirm BioSciences Gets High Marks for Accuracy and Quality in National Institutes of Health Research

6/11/20 – UC San Diego

Pioneering Scientist and Innovator Larry Smarr Retires

6/10/20 – Illumina

Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test

6/10/20 – ChromaCode

FDA Issues Emergency Use Authorization for ChromaCode's High-Throughput HDPCR™ SARS-CoV-2 Real-Time PCR Assay

6/10/20 – Dermata Therapeutics

Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris

6/9/20 – Bolt Therapeutics

Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody™ ISAC Technology and its Lead Development Candidate, BDC-1001

6/9/20 – Revolution Medicines

Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study

6/9/20 – Cardiff Oncology

Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

6/9/20 – Fate Therapeutics

Fate Therapeutics Announces Pricing of Public Offering of Common Stock

6/9/20 – DFIN

Leading BioSciences: Teams With Donnelley Financial Solutions to Create Innovative Study Tool for Clinical Trial Monitoring During COVID-19 Pandemic

6/8/20 – KUSI

Sorrento Therapeutics is developing “COVIDTRAP” protein to bind and block the coronavirus

6/8/20 – Amplyx Pharmaceuticals

Amplyx Pharmaceuticals Expands Executive Leadership Team

6/8/20 – Retrophin

Retrophin Announces Pricing of Public Offering of Common Stock

6/8/20 – Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study

6/8/20 – Neurocrine

Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

6/8/20 – Dow Jones

Avidity Biosciences Sets IPO at 10 Million Shares; Sees Pricing at $14-$16 Each

6/4/20 – Halozyme

Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

6/4/20 – Nektar Therapeutics

Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)